Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO: Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization)

Trial Profile

A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO: Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Artesunate (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Imatinib (Primary) ; Infliximab (Primary) ; Metablok-Arch Biopartners (Primary) ; Lopinavir/ritonavir
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Acronyms CATCO
  • Most Recent Events

    • 12 Oct 2023 Planned primary completion date changed from 18 Mar 2023 to 10 Mar 2024.
    • 12 Oct 2023 Status changed from recruiting to active, no longer recruiting.
    • 26 Apr 2022 Treatments section has been updated to replace Losartan with Angiotensin II receptor blockers. The type of ARB received will be dependent on what is available at the hospitals.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top